John Cox, Dyne Therapeutics CEO
Dyne Therapeutics sharpens case for two muscle disease therapies with updated data
Dyne Therapeutics shared promising clinical trial updates from two of its experimental RNA medicines for myotonic dystrophy type 1 (DM1) and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
